---
title: "Su-Leng Tan Lee Discloses Investment at BioNexus Gene Lab Corp with 11.5% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295980100.md"
description: "Su-Leng Tan Lee, CEO and President of BioNexus Gene Lab Corp, disclosed an 11.5% stake in the company via a Schedule 13D filing on Aug. 14, 2026. The shares were granted as compensation for completed services rather than to acquire control. Tan stated she has no present plans to change strategy or governance, though she retains the right to reassess actions subject to fiduciary duties."
datetime: "2026-08-14T21:36:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295980100.md)
  - [en](https://longbridge.com/en/news/295980100.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295980100.md)
generator: "portal-rs"
---

# Su-Leng Tan Lee Discloses Investment at BioNexus Gene Lab Corp with 11.5% Stake

Su-Leng Tan Lee, Chief Executive Officer, President, and director of BioNexus Gene Lab Corp, disclosed ownership of an 11.5% stake in the company’s common stock. The company granted 338,709 fully vested shares on Aug. 13, 2026, as compensation for completed services, and filed the Schedule 13D on Aug. 14, 2026. The award carried no cash consideration and was issued offshore under Regulation S.

**Investor Intent**

Tan acquired the shares as compensation and not to take control of BioNexus Gene Lab Corp. She leads the company and, because of her roles, may consider or support actions on strategy, governance, capital structure, and leadership as part of ongoing management. She states, "The shares were not acquired ... for the purpose of acquiring control," and adds, "I have no present plan or proposal" for actions listed in Item 4(a)–(j), while reserving the ability to reassess over time subject to fiduciary duties and approvals.

**Investor's Background**

Su-Leng Tan Lee is the Chief Executive Officer and President of BioNexus Gene Lab Corp and serves on its Board of Directors. BioNexus operates in molecular diagnostics and the distribution of industrial chemicals, with operations centered in Malaysia. As a leader-operator, Tan focuses on execution, governance, and long-term growth of the business and holds equity awards aligned with company performance.

Original SEC Filing: BioNexus Gene Lab Corp \[ BGLC \] - SCHEDULE 13D - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BGLC.US](https://longbridge.com/en/quote/BGLC.US.md)

## Related News & Research

- [BioNexus Gene Lab files initial beneficial ownership statement for Fidelion Diagnostics Pte. Ltd](https://longbridge.com/en/news/295275069.md)
- [Professional Diversity Network to execute 1-for-30 reverse stock split Sept. 11](https://longbridge.com/en/news/298603909.md)
- [Soho Global Health says unaware of any material information behind share-trade volatility](https://longbridge.com/en/news/298679681.md)
- [Lithium Americas VP Corporate Development Alexi Zawadzki retires Sept. 11](https://longbridge.com/en/news/298727944.md)
- ['I saw Terminator 2 too': Y Combinator's Garry Tan pushes back on AI extinction fears](https://longbridge.com/en/news/298692990.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**